Caroline Seymour

The FDA has accepted the resubmission of the BLA seeking the approval of denileukin diftitox-cxdl for relapsed/refractory cutaneous T-cell lymphoma.

Olaparib plus cediranib failed to improve PFS and OS vs chemotherapy in patients with platinum-resistant or -refractory epithelial ovarian cancer.

The FDA’s Oncologic Drugs Advisory Committee voted in favor of imetelstat for select patients with lower-risk myelodysplastic syndrome.

A high proportion of patients with metastatic solid tumors experienced stable disease following treatment with the immunocytokine in the DODEKA trial.

Peter A. Humphrey, MD, PhD, presents on the standing of artificial intelligence in prostate cancer pathology.

The inter-tumoral complexity of metastatic castration-resistant prostate cancer poses a treatment challenge that may be tackled by examining clonal evolution.

The addition of UV1 to nivolumab/ipilimumab failed to improve PFS in the frontline treatment of unresectable or metastatic melanoma.

Eftilagimod alpha in combination with chemotherapy displayed a manageable safety profile in HR+/HER2-low breast cancer.

The UK’s NICE has announced that it will not recommend the use of trastuzumab deruxtecan for the treatment of patients with HER2-low breast cancer.

Frontline maintenance therapy with avelumab following platinum-based chemotherapy led to similar outcomes in routine clinical practice and the JAVELIN Bladder 100 trial in metastatic urothelial cancer.

Ashish Saxena, MD, PhD, discusses the movement of targeted and immune therapies in non–small cell lung cancer treatment.

The FDA has approved a label expansion for ibrutinib with an oral suspension formulation in all current indications.

Rusfertide displayed activity in phlebotomy-dependent polycythemia vera.

The FDA has determined that sufficient criteria have been met to withdraw the approval for melphalan flufenamide in patients with multiple myeloma.

A BLA seeking the approval of datopotamab deruxtecan in pretreated nonsquamous non–small cell lung cancer is under review by the FDA.

Investigation of RVT-2001 will be discontinued following an insufficient display of benefit in patients with myelodysplastic syndrome.

BXCL701 has been granted fast track designation for select patients with metastatic small cell neuroendocrine prostate cancer by the FDA.

R. Lor Randall, MD, FACS, explains the next steps in ensuring adherence to clinical care guidelines in extremity sarcoma.

Apalutamide plus androgen deprivation therapy improved prostate-specific antigen progression-free survival in castration-sensitive prostate cancer.

Belantamab mafodotin plus bortezomib and dexamethasone improved PFS vs daratumumab plus bortezomib and dexamethasone in relapsed/refractory myeloma.

FDA grants fast-track status to BNT325/DB-1305 for patients with platinum-resistant ovarian epithelial, fallopian tube, or primary peritoneal cancer.

The EMA has accepted for review an MAA seeking the approval of linvoseltamab for use in select patients with relapsed/refractory multiple myeloma.

The FDA has granted a fast track designation to the T-cell therapy BST02 for the treatment of patients with all forms of liver cancer.

VDA-1102 led to an objective response rate of 56% in patients with mycosis fungoides, according to findings from an interim analysis of a phase 2a study.

Enfortumab vedotin plus pembrolizumab showed consistent overall survival and progression-free survival benefit in all patients enrolled in EV-302.

NICE has recommended talazoparib for the treatment of patients with advanced or metastatic HER2-negative breast cancer with germline BRCA1/2 mutations.

PFS was significantly improved with durvalumab plus bevacizumab and TACE vs TACE alone in patients with unresectable HCC eligible for embolization.

The FDA has granted an orphan drug designation to PTX-252 for the treatment of patients with acute myeloid leukemia.

Treatment with THIO followed by cemiplimab-rwlc led to a high DCR regardless of dose level in patients with pretreated non–small cell lung cancer.

Treatment with TLD-1433 led to 6-, 12-, and 15-month CR rates of 54%, 38%, and 37%, respectively, in patients with non–muscle invasive bladder cancer.